Abstract
Psoriasis is a common, chronic and disabling skin disorder affecting approximately 2% of the population, associated with significant negative impact on the patient’s quality of life. Approximately 80% of those affected with psoriasis have mild-to-moderate forms and are usually treated with topical therapy, whereas phototherapy and systemic therapies are used for those with severe disease. In the past three decades, the major advances in psoriasis therapy have been in systemic agents for the treatment of moderate-to-severe psoriasis, particularly new immunomodulatory and biological molecules, while topical therapies have remained relatively unchanged over the past decades. Indeed, topical corticosteroids and vitamin D3 analogs are still the gold standard of therapy for mild-to-moderate psoriasis. Thus, there is a need to develop new and more effective topical agents in the short and long term, with a better efficacy and safety profile than corticosteroids and vitamin D3 analogs. Over the past five years, investigation into topical therapy has expanded, with exciting new drugs being developed. Preliminary results of these emerging agents that selectively target disease-defining pathogenic pathways seem to be promising, although long-term and large-scale studies assessing safety and efficacy are still lacking. The aim of this article was to review the clinical and research data of some emerging topical agents, focusing on Janus kinase–signal transducer and activator of transcription and phosphodiesterase type 4 inhibitors, which are currently being investigated.
Similar content being viewed by others
References
Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 535–46.
Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27: 12–29.
Puig L, Kirby B, Mallbris L, Strohal R. Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological comorbidities of psoriasis. Eur J Dermatol 2014; 24: 305–11.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–71.
Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr 2014; 105: 9–20.
Chiricozzi A, Saraceno R, Chimenti MS, Guttman-Yassky E, Krueger JG. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets 2014; 18: 513–25.
Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol 2013; 69: 931–7.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643–59.
Ghoreschi K, Gadina M, Jakpot M. New small molecules in autoimmune and inflammatory diseases. Exp Dermatol 2014; 23: 7–11.
Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178: 2623–9.
Hsu L, Armstrong AW. JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis. J Immunol Res 2014; 2014: 283617.
Chiricozzi A, Faleri S, Saraceno R, et al. Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Rev Clin Immunol 2015; 11: 443–55.
Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep 2014; 16: 443.
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186: 4234–43.
Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled doseranging study. Br J Dermatol 2012; 167: 668–77.
Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and re-treatment in moderate-to-severe chronic plaque psoriasis: a randomised controlled trial. Br J Dermatol 2015; 172: 1395–406.
Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169: 137–45.
Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 2011; 131: 1838–44.
Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67: 658–64.
Callis Duffin K, Luchi M, Fidelus-Gort R. Novel mechanism for topical treatment of plaque psoriasis–results of a randomized, doubleblind, concentration ranging, vehicle controlled 12 week study with JAK 1/2 inhibitor INCB018424 cream. J Invest Dermatol 2010; 130 Suppl. (Abstract 261) Presented at: Society for Investigative Dermatology 2010 Annual Meeting. May 8-10, 2010. Atlanta, GA.
Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with topical JAK1/JAK2 inhibitor. Br J Dermatol 2015; 173: 989–97.
Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014; 26: 2016–29.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83: 1583–90.
Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb) 2013; 3: 1–15.
Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs 2014; 74: 825–37.
Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potencial topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009; 10: 1236–42.
Merck Sharp & Dohme Corp. A Double Blind, Active-Comparator-, and Vehicle-Controlled, Multiple-Dose Study to Evaluate the Efficacy and Pharmacokinetics of MK-0873 in Patients With Plaque Psoriasis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: https://clinicaltrials.gov/show/NCT01235728 NLM Identifier: NCT01235728.
Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg 2014; 33: S37–41.
Kragballe K, van de Kerkhof PC, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol 2014; 24: 523–32.
Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv 2012; 9: 1263–71.
Martin SL, McGoey ST, Bebo BF Jr., Feldman SR. Patients’ educational needs about topical treatments for psoriasis. J Am Acad Dermatol 2013; 68: e163–8.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Rafael, A., Torres, T. Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol 26, 3–8 (2016). https://doi.org/10.1684/ejd.2015.2663
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2015.2663